

In Vivo Aortic Valve Thermal Heterogeneity in Patients With Nonrheumatic Aortic Valve Stenosis

The First In Vivo Experience in Humans

Konstantinos Toutouzas, MD,* Maria Drakopoulou, MD,* Andreas Synetos, MD,* Eleftherios Tsiamis, MD,* George Agrogiannis, MD,† Nikolaos Kavantzias, MD,† Eustratios Patsouris, MD,† Dimitris Iliopoulos, MD,‡ Stergios Theodoropoulos, MD,§ Magdi Yacoub, MD,§|| Christodoulos Stefanadis, MD*

Athens, Greece; and London, United Kingdom

- Objectives** We investigated in vivo in aortic valve stenosis (AVS) whether there is: 1) thermal heterogeneity within the valve leaflets; 2) temperature difference between the leaflets and the ascending aortic wall; and 3) a possible correlation between heat production, inflammation, and neoangiogenesis.
- Background** Histological studies have demonstrated a potential role of inflammation and neoangiogenesis in AVS.
- Methods** We examined 96 leaflets scheduled for aortic valve replacement. Twenty-five patients had AVS, and 7 had aortic valve insufficiency (AVI). Temperature measurements were performed right before hypothermic cardioplegia. Temperature difference (ΔT) was assigned as the mean temperature of each leaflet minus the temperature of the aortic wall. Histological, immunohistological analysis, and vascular endothelial growth factor (VEGF) immunoreactivity was performed.
- Results** Significant thermal heterogeneity was recorded within the leaflets of AVS, compared with AVI ($1.52 \pm 1.35^\circ\text{C}$ vs. $0.13 \pm 0.11^\circ\text{C}$, $p < 0.01$). In AVS ΔT was greater in all leaflets compared with the AVI group ($p < 0.01$). Leaflets of AVS had increased inflammatory cell infiltration, calcium deposit, and anti-VEGF expression compared with AVI ($p < 0.01$).
- Conclusions** Thermal heterogeneity is increased in AVS and correlates with inflammatory mononuclear cell infiltration, expression of pro-inflammatory cytokines and neoangiogenic factors. (J Am Coll Cardiol 2008;52:758–63)
© 2008 by the American College of Cardiology Foundation

The prevalence of aortic valve stenosis (AVS) increases with age and is the most common reason for valve replacement (1–4). Several studies have shown that local infiltration of inflammatory cells within leaflets of AVS is a prominent feature of aortic valve calcification. In addition to inflammation, neoangiogenesis has been described in severe AVS, similarly to atherosclerotic lesions (3,5).

See page 764

We postulated that the inflammatory activation within the aortic valves might generate heat (6,7). We investigated

in vivo in patients with AVS whether there is: 1) thermal heterogeneity within the leaflets; 2) temperature difference between the leaflets and the ascending aortic wall; and 3) a possible correlation between heat production, inflammation, and neoangiogenesis.

Methods

Study population. We examined 96 leaflets scheduled for aortic valve replacement. Twenty-five patients had AVS, and 7 had aortic valve insufficiency (AVI) (control group). Patients with known coronary artery disease, ejection fraction $<50\%$, rheumatic fever in their medical history, intercurrent inflammatory or neoplastic condition, or those medicated with anti-inflammatory drugs except for aspirin were excluded from the study. Cardiac catheterization was performed to exclude the presence of coronary artery disease (stenoses $\geq 50\%$). The Ethics Committee of all institutions approved the study protocol.

From the *First Department of Cardiology, Hippokraton Hospital, Athens and the †Department of Pathology, Athens Medical School, Athens, Greece; ‡Department of Cardiosurgery, Iatriko Kentro, Marousi, Athens, Greece; §Department of Cardiosurgery, Iasso General Hospital, Athens, Greece; and the ||Imperial College Heart Science Center, Harefield Hospital, London, United Kingdom.

Manuscript received January 30, 2008; revised manuscript received March 19, 2008, accepted April 5, 2008.

Procedure. After cardiopulmonary bypass was started, the ascending aorta was cross-clamped. Temperature measurements were obtained at this stage (see temperature measurements in the following text) right before the hypothermic cardioplegia.

In vivo measurements. A thermographic catheter with a sensitive thermistor at the distal tip was used (BetaTHERM sensor, Galway, Ireland). After preparation of the field for clear visualization of the valve leaflets and exclusion of macroscopically atherosclerotic lesions on the aortic wall, the thermistor was placed on each leaflet 5 times, and the maximal, minimal, and mean temperature was obtained. The thermistor was applied on the internal aortic wall 5 times, and the average temperature was assigned as the aortic wall temperature. "Thermal heterogeneity" within the leaflets was assigned as the maximal temperature between the leaflets minus the minimal temperature between the leaflets.

"Temperature difference" (ΔT) was assigned as the mean temperature of each leaflet minus the mean temperature of the aortic wall. "Maximal ΔT " was assigned as the maximal temperature between the leaflets minus the temperature of the aortic wall. Aortic valves were then harvested.

Ex vivo measurements. In 10 additional valves of patients with AVS, ex vivo temperature measurements were performed, immediately after extraction, in a humidified incubator (SANYO, Osaka, Japan) at 37°C in normoxic conditions.

Histological and immunohistochemical analysis. All samples were fixed in 10% buffered formalin for 24 h, decalcified overnight with formic acid, and processed for routine paraffin embedding. Each leaflet was then divided radially, and 5- μ m-thick sections were obtained from paraffin-embedded samples and stained with hematoxylin-eosin staining (3). Histological sections were analyzed semiquantitatively as previously described (5,8,9).

Immunohistochemical staining for cluster of differentiation 3 (CD3), tumor necrosis factor (TNF)- α , interleukin (IL)-6, and vascular endothelial growth factor (VEGF) was performed by standard immunohistochemistry including antigen retrieval. The following primary antibodies were used: anti CD3, (Dako, Glostrup, Denmark), anti-TNF- α , (RnD, Minneapolis, Minnesota), anti-IL-6, (RnD), anti-VEGF, (Becton Dickinson, Franklin Lakes, New Jersey). For negative controls, the primary antibody was omitted and replaced by nonimmune serum. Finally, slides were counterstained with hematoxylin and mounted.

Evaluation of hematoxylin-eosin staining and immunohistochemistry was performed independently and blindly on the groups included by 2 pathologists. For the evaluation of immunohistochemistry, CD3 staining was graded according to the degree of inflammation. The expression of TNF- α and IL-6 was graded according to previous studies (10). The VEGF quantification was performed semiquantitatively as previously described (11).

Statistical analysis. Statistical analysis was performed with the commercially available software (SPSS Inc., Chicago, Illinois). Quantitative data are presented as rates or mean value \pm SD. Probability values are 2-sided from the Student *t* test for continuous variables. Noncontinuous values were compared by the chi-square test. For all histological and immunohistological measurements, interobserver and intraobserver variability was assessed by reanalysis of a representative sample of histological sections. A value of *p* < 0.05 was considered significant.

Abbreviations and Acronyms

- AVI** = aortic valve insufficiency
- AVS** = aortic valve stenosis
- CD3** = cluster of differentiation 3
- IL** = interleukin
- TNF** = tumor necrosis factor
- VEGF** = vascular endothelial growth factor
- ΔT** = temperature difference

Table 1 Baseline Demographic and Clinical Characteristics

	AVS	AVI	p Value
Clinical variables			
Age, yrs (mean \pm SD)	68.2 \pm 10.52	59.14 \pm 13.52	0.06
Male gender	18 (72%)	5 (71.4%)	0.99
Hypertension	16 (64.0%)	4 (57.1%)	0.99
Hyperlipidemia	8 (32.0%)	3 (42.8%)	0.67
Diabetes mellitus	6 (24%)	2 (28.5%)	0.99
Smoking status	8 (32.0%)	3 (42.8%)	0.67
EF (%)	59.04 \pm 6.68	59.57 \pm 4.61	0.84
Previous medication			
ACE-Is	17 (68.0%)	4 (57.1%)	0.67
Statins	8 (32.0%)	3 (42.0%)	0.67
Calcium-channel blockers	6 (24.0%)	3 (42.0%)	0.37
Beta-blockers	6 (24.0%)	2 (28.5%)	0.99
Diuretics	6 (24.0%)	1 (14.3%)	0.99

ACE-I = angiotensin-converting enzyme inhibitor; AVI = aortic valve insufficiency; AVS = aortic valve stenosis; EF = ejection fraction.

Results


Baseline demographic and clinical characteristics. The procedure was safe and without complications. The baseline clinical and demographic characteristics are demonstrated in Table 1.

Thermographic findings. IN VIVO MEASUREMENTS. Significant thermal heterogeneity was recorded in the AVS compared with the AVI group. Mean and maximal ΔT was greater in the AVS compared with the AVI group (Table 2).


Table 2 In Vivo ΔT of Aortic Valves in Patients With AVS and AVI

	Thermal Heterogeneity	Mean ΔT	Maximal ΔT
AVS ($^{\circ}$ C)	1.52 \pm 1.35	1.28 \pm 0.93	1.96 \pm 1.16
AVI ($^{\circ}$ C)	0.13 \pm 0.11	0.06 \pm 0.15	0.13 \pm 0.13
p value	0.01	<0.01	<0.01

ΔT = temperature difference; other abbreviations as in Table 1.



In AVS leaflets, ΔT was greater compared with the AVI group (noncoronary: $1.09 \pm 1.16^\circ\text{C}$ vs. $0.10 \pm 0.10^\circ\text{C}$; right: $1.24 \pm 1.03^\circ\text{C}$ vs. $0.02 \pm 0.19^\circ\text{C}$; left: $1.53 \pm 1.23^\circ\text{C}$ vs. $0.05 \pm 0.19^\circ\text{C}$; $p < 0.01$ for all comparisons). There was no difference



in ΔT between the 3 leaflets in both groups (AVS: $p = 0.67$, AVI: $p = 0.72$). When analyzed by statin intake, mean ΔT did not differ between the 2 groups ($p = 0.49$).

EX VIVO MEASUREMENTS. Thermal heterogeneity before and after excision was not significant ($1.15 \pm 0.75^\circ\text{C}$ vs. $1.07 \pm 0.73^\circ\text{C}$, $p = 0.40$).

Histological analysis. There was no significant difference in the interobserver and intraobserver readings. Inflammatory infiltrates were present in all samples, in small aggregate areas around substantial calcium deposits or diffused throughout the leaflets, on the aortic or ventricular side of the subendothelial layers. The T-lymphocytes, monocytes, and plasma cells were the most predominant cells in these infiltrates. Dense lymphocyte infiltration was observed in 97.8% of AVS versus 0% of AVI ($p < 0.01$) (Fig. 1). Increased infiltration from mast cells and calcium deposit was detected in all leaflets from AVS versus none from AVI ($p < 0.01$) (Table 3).

Immunohistochemistry. All specimens from AVS were positive for CD3-, TNF- α , and IL-6, in contrast to

Table 3 **Immunohistological Analysis of Aortic Valve Leaflets Between the 2 Groups of Patients**

Grade	AVS (n = 75)				AVI (n = 21)			
	0	1+	2+	3+	0	1+	2+	3+
Histological features, n (%)								
T lymphocytes	0 (0%)	2 (2.6%)	9 (12%)	64 (85.4%)	19 (90.4%)*	2 (9.6%)	0 (0%)*	0 (0%)*
Mast cells	0 (0%)	0 (0%)	10 (14%)	65 (86%)	17 (81%)*	4 (9%)*	0 (0%)*	0 (0%)*
Calcium deposits	0 (0%)	0 (0%)	2 (3%)	73 (97%)	16 (76%)*	5 (23%)*	0 (0%)	0 (0%)*
Immunohistological features, n (%)								
CD3	0 (0%)	1 (1.3%)	8 (10.6%)	66 (88%)	17 (80.9%)*	4 (19.0%)*	0 (0%)	0 (0%)*
TNF- α	0 (0%)	2 (2.7%)	12 (16%)	61 (81.3%)	16 (76.2%)*	5 (23.8%)*	0 (0%)*	0 (0%)*
IL-6	0 (0%)	2 (0%)	13 (17.3%)	60 (80%)	17 (80.9%)*	4 (19.0%)*	0 (0%)*	0 (0%)*

* $p < 0.05$ for comparisons between aortic valve stenosis (AVS) and aortic valve insufficiency (AVI).
 CD3 = cluster of differentiation 3; IL = interleukin; TNF = tumor necrosis factor.

negative specimens of the AVI group (Figs. 2 to 4). Intense expression of inflammatory indexes was found in the AVS compared with the AVI group (Table 3). We categorized specimens into 2 groups with a cut-off value of 2 on the basis of the semiquantitative scale for CD3, TNF- α , IL-6, calcium deposit, mast cell, and T lymphocyte expression. Mean ΔT was greater in leaflets with intense compared with low expression of CD3, TNF- α , and IL-6 (CD-3: $1.26 \pm 1.11^\circ\text{C}$ vs. $0.51 \pm 1.01^\circ\text{C}$; TNF- α : $1.38 \pm 1.13^\circ\text{C}$ vs. $0.39 \pm 0.83^\circ\text{C}$; IL-6: $1.35 \pm 1.12^\circ\text{C}$ vs. $0.49 \pm 0.95^\circ\text{C}$, $p < 0.01$ for all comparisons) (Figs. 5A to 5C).

Mean ΔT was greater in leaflets with intense compared with low expression of calcium deposit ($1.33 \pm 1.11^\circ\text{C}$ vs. $0.02 \pm 0.25^\circ\text{C}$, $p < 0.01$). In leaflets with AVS and intense expression of mast cells, mean ΔT was greater compared with leaflets with low expression ($1.52 \pm 1.01^\circ\text{C}$ vs. $0.26 \pm 0.67^\circ\text{C}$, $p < 0.01$). In leaflets with AVS and intense expression of T lymphocytes, mean ΔT was greater com-




Figure 3 Representative Photomicrographs of Anti-TNF- α Staining in Examined Specimens of Aortic Valves

(A) Anti-tumor necrosis factor (TNF)- α staining in aortic valve stenosis. Arrows indicate positivity to anti-TNF- α . (B) Anti-TNF- α staining in aortic valve insufficiency showing negative staining for anti-TNF- α ($\times 400$).




Figure 4 Representative Photomicrographs of IL-6 Staining in Examined Specimens of Aortic Valves

(A) Interleukin (IL)-6 staining in aortic valve stenosis. Arrows indicate IL-6 immunopositive inflammatory cells in the valve stroma ($\times 400$). (B) The IL-6 staining in aortic insufficiency showing negative staining for IL-6 ($\times 400$).


pared with leaflets with low expression ($0.54 \pm 1.00^\circ\text{C}$ vs. $0.21 \pm 0.66^\circ\text{C}$, $p < 0.01$).

VEGF immunoreactivity. Neoangiogenesis was evident in all AVS specimens, in areas where inflammatory infiltrates were denser, in contrast to AVI (Fig. 6, Table 4). Mean ΔT was greater in leaflets with a high compared with a low degree of VEGF immunoreactivity ($1.28 \pm 1.14^\circ\text{C}$ vs. $0.18 \pm 0.38^\circ\text{C}$, $p < 0.01$) (Fig. 5D).

Discussion

The main finding of this study is that nonrheumatic aortic stenotic valves have *in vivo* significant thermal heterogeneity that correlates with inflammatory infiltrates and neovessels, supporting the hypothesis that an active inflammatory process is involved.

Calcific aortic valve disease has been recognized as an active process with features of chronic inflammation (12). We therefore evaluated local inflammatory process at the



leaflets of AVS by thermography, because it is the only method currently available to measure heat generation reflecting inflammation (13,14). According to our results there is a significant difference in local inflammatory activation within aortic valve leaflets as well as between the leaflets of the same stenotic valve. This difference was associated with increased inflammatory cell infiltration, such as T-lymphocytes and mast cells, in accordance with previous observations (15). Other studies have shown that increased inflammatory markers are attributed to shared risk factors with cardiovascular disease and infiltration of lipoproteins and interstitial cells (16,17). Inhibition of the inflammatory activation, possibly by statins (18,19) although not demonstrated in the current study, might be a beneficial pharmacological prevention of AVS.

Study limitations. We performed ex vivo measurements from AVS specimens to verify that temperature measurements were not altered right before hypothermical cardioplegia. In vivo measurements during cardiac catheterization would be the ideal method; however, the impact of the cooling effect of blood flow on thermography could not have been eliminated (20). Furthermore, we used as a reference temperature the temperature of the aortic wall. Although we macroscopically selected areas without atherosclerotic lesions, we cannot exclude the presence of small lesions with inflammatory activation, leading to underestimation of the temperature difference between the aortic wall and aortic valve. In addition, further subgroup analysis is limited by the small number of stenotic aortic valves with low inflamma-


tory activation. Finally, patients with AVI comprised the control group, because “normal” heart valves cannot be used. **Clinical implications.** The present study supports the hypothesis that an active inflammatory process is involved in AVS. Anti-inflammatory treatment and statin intake in such patients might have significant prognostic and therapeutic implications. Future studies need to be performed for further evaluation.

Conclusions

Nonrheumatic aortic stenotic valves have in vivo significant thermal heterogeneity reflecting an active local inflammatory activation. Neoangiogenesis, local inflammatory activation, and thermal heterogeneity are increased in AVS. Further studies need to be performed to investigate whether prevention of neoangiogenesis might have significant prognostic and therapeutic implications.

Table 4 Semiquantitative VEGF Immunoreactivity Between Leaflets of Patients With AVS and Patients With AVI		
	AVS (n = 75)	AVI (n = 21)
	0 (0%)	16 (76.2%)*
++	0 (0%)	5 (23.8%)*
+++	4 (5.3%)	0 (0%)*
++++	6 (8.0%)	0 (0%)*
+++++	65 (86.6%)	0 (0%)*

*p < 0.05 for comparisons between aortic valve stenosis (AVS) and aortic valve insufficiency (AVI). VEGF = vascular endothelial growth factor.



Reprint requests and correspondence: Dr. Konstantinos Toutouzas, 26 Karaoli and Dimitriou Street, Holargos, 15562 Athens, Greece. E-mail: ktoutouz@otenet.gr.

REFERENCES

1. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. *Circulation* 1994;90:844–53.
2. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L, Nilsson J. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. *J Am Coll Cardiol* 1994;23:1162–70.
3. Mazzone A, Epistolato MC, De Caterina R, et al. Neovascularization, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. *J Am Coll Cardiol* 2004;43:1670–6.
4. Chandra HR, Goldstein JA, Choudhary N, et al. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. *J Am Coll Cardiol* 2004;43:169–75.
5. Mazzone A, Epistolato MC, Gianetti J, et al. Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: two different sites of the same disease? *Am J Clin Pathol* 2006;126:494–502.
6. Stefanadis C, Diamantopoulos L, Vlachopoulos C, et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: a new method of detection by application of a special thermography catheter. *Circulation* 1999;99:1965–71.
7. Verheye S, Kockx MM, Casscells SW. Thermography to detect inflamed macrophage-rich plaques. *Circulation* 2003;107:e212–3, author reply e212–3.
8. Wallby L, Janerot-Sjoberg B, Steffensen T, Broqvist M. T lymphocyte infiltration in nonrheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. *Heart* 2002;88:348–51.
9. Warren BA, Yong JL. Calcification of the aortic valve: its progression and grading. *Pathology* 1997;29:360–8.
10. Guilherme L, Cury P, Demarchi LM, et al. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. *Am J Pathol* 2004;165:1583–91.
11. Stefanadis C, Toutouzas K, Stefanadi E, Lazaris A, Patsouris E, Kipshidze N. Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: an experimental study. *Atherosclerosis* 2007;195:269–76.
12. O'Brien KD. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). *Arterioscler Thromb Vasc Biol* 2006;26:1721–8.
13. Stefanadis C, Chrysochoou C, Markou D, et al. Increased temperature of malignant urinary bladder tumors in vivo: the application of a new method based on a catheter technique. *J Clin Oncol* 2001;19:676–81.
14. Casscells W, Hathorn B, David M, et al. Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis. *Lancet* 1996;347:1447–51.
15. Helsing S, Syvaranta S, Kupari M, et al. Possible role for mast cell-derived cathepsin G in the adverse remodeling of stenotic aortic valves. *Eur Heart J* 2006;27:1495–504.
16. Fox CS, Guo CY, Larson MG, et al. Relations of inflammation and novel risk factors to valvular calcification. *Am J Cardiol* 2006;97:1502–5.
17. Agmon Y, Khandheria BK, Jamil Tajik A, et al. Inflammation, infection, and aortic valve sclerosis: Insights from the Olmsted County (Minnesota) population. *Atherosclerosis* 2004;174:337–42.
18. Osman L, Yacoub MH, Latif N, Amrani M, Chester AH. Role of human valve interstitial cells in valve calcification and their response to atorvastatin. *Circulation* 2006;114:I547–52.
19. Osman L, Chester AH, Amrani M, Yacoub MH, Smolenski RT. A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin. *Circulation* 2006;114:I566–72.
20. Stefanadis C, Toutouzas K, Tsiamis E, et al. Thermal heterogeneity in stable human coronary atherosclerotic plaques is underestimated in vivo: the "cooling effect" of blood flow. *J Am Coll Cardiol* 2003;41:403–8.

Key Words: aortic valve ■ inflammation thermography.